Maternal methadone dose, placental methadone concentrations, and neonatal outcomes.

BACKGROUND Few investigations have used placenta as an alternative matrix to detect in utero drug exposure, despite its availability at the time of birth and the large amount of sample. Methadone-maintained opioid-dependent pregnant women provide a unique opportunity to examine the placental disposition of methadone and metabolite [2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP)], to explore their correlations with maternal methadone dose and neonatal outcomes, and to test the ability to detect in utero exposure to illicit drugs. METHODS We calculated the correlations of placental methadone and EDDP concentrations and their correlations with maternal methadone doses and neonatal outcomes. Cocaine- and opiate-positive placenta results were compared with the results for meconium samples and for urine samples collected throughout gestation. RESULTS Positive correlations were found between placental methadone and EDDP concentrations (r=0.685), and between methadone concentration and methadone dose at delivery (r=0.542), mean daily dose (r=0.554), mean third-trimester dose (r=0.591), and cumulative daily dose (r=0.639). The EDDP/methadone concentration ratio was negatively correlated with cumulative daily dose (r=-0.541) and positively correlated with peak neonatal abstinence syndrome (NAS) score (r=0.513). Placental EDDP concentration was negatively correlated with newborn head circumference (r=-0.579). Cocaine and opiate use was detected in far fewer placenta samples than in thrice-weekly urine and meconium samples, a result suggesting a short detection window for placenta. CONCLUSIONS Quantitative methadone and EDDP measurement may predict NAS severity. The placenta reflects in utero drug exposure for a shorter time than meconium but may be useful when meconium is unavailable or if documentation of recent exposure is needed.

[1]  M. Huestis,et al.  Simultaneous quantification of methadone, cocaine, opiates, and metabolites in human placenta by liquid chromatography-mass spectrometry. , 2009, Journal of analytical toxicology.

[2]  M. Huestis,et al.  Simultaneous quantification of buprenorphine, norbuprenorphine, buprenorphine glucuronide, and norbuprenorphine glucuronide in human placenta by liquid chromatography mass spectrometry , 2009, Analytical and bioanalytical chemistry.

[3]  M. Huestis,et al.  A liquid chromatography tandem mass spectrometry method for the simultaneous quantification of 20 drugs of abuse and metabolites in human meconium , 2009, Analytical and bioanalytical chemistry.

[4]  J. Atta-Politou,et al.  Validated method for the simultaneous determination of methadone and its main metabolites (EDDP and EMDP) in plasma of umbilical cord blood by gas chromatography-mass spectrometry. , 2008, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[5]  R. Nanan,et al.  Methadone Maintenance and Breastfeeding in the Neonatal Period , 2008, Pediatrics.

[6]  M. Huestis,et al.  Methadone Maintenance and Breastfeeding in the Neonatal Period , 2008, Pediatrics.

[7]  M. Huestis,et al.  Validation of a LC-APCI-MS/MS method for quantification of methadone, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) and 2-ethyl-5-methyl-3,3-diphenylpyraline (EMDP) in infant plasma following protein precipitation. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[8]  M. Huestis,et al.  Concentrations of Methadone in Breast Milk and Plasma in the Immediate Perinatal Period , 2007, Journal of human lactation : official journal of International Lactation Consultant Association.

[9]  S. Pichini,et al.  Neonatal withdrawal syndrome after chronic maternal drinking of mate. , 2007, Therapeutic drug monitoring.

[10]  R. Pacifici,et al.  Confirmation of gestational exposure to alprazolam by analysis of biological matrices in a newborn with neonatal sepsis , 2007, Clinical toxicology.

[11]  H. Jones,et al.  Mood disorders affect drug treatment success of drug-dependent pregnant women. , 2007, Journal of substance abuse treatment.

[12]  A. Bermejo,et al.  Determination of methadone, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine and alprazolam in human plasma by liquid chromatography-electrospray ionization mass spectrometry. , 2006, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[13]  M. Strolin Benedetti,et al.  Differences in absorption, distribution, metabolism and excretion of xenobiotics between the paediatric and adult populations , 2005, Expert opinion on drug metabolism & toxicology.

[14]  B. Lester,et al.  Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. , 2005, Drug and alcohol dependence.

[15]  R. Pacifici,et al.  Prenatal exposure to arecoline (areca nut alkaloid) and birth outcomes , 2005, Archives of Disease in Childhood - Fetal and Neonatal Edition.

[16]  H. Jones,et al.  Determination of methadone, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine, 2-ethyl-5-methyl-3,3-diphenylpyraline and methadol in meconium by liquid chromatography atmospheric pressure chemical ionization tandem mass spectrometry. , 2005, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[17]  G. Hankins,et al.  Bidirectional transfer of methadone across human placenta. , 2005, Biochemical pharmacology.

[18]  H. Jones,et al.  Neonatal abstinence syndrome in methadone-exposed infants is altered by level of prenatal tobacco exposure. , 2004, Drug and alcohol dependence.

[19]  E. Kharasch,et al.  Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone , 2004, Clinical pharmacology and therapeutics.

[20]  R. Couch,et al.  Can methadone concentrations predict the severity of withdrawal in infants at risk of neonatal abstinence syndrome? , 2004, Archives of Disease in Childhood - Fetal and Neonatal Edition.

[21]  G. Hankins,et al.  Methadone metabolism by human placenta. , 2004, Biochemical pharmacology.

[22]  J. Keelan,et al.  Drug Transfer and Metabolism by the Human Placenta , 2004, Clinical pharmacokinetics.

[23]  J. Kinsella Meconium aspiration syndrome: is surfactant lavage the answer? , 2003, American journal of respiratory and critical care medicine.

[24]  M. Huestis,et al.  Drug abuse's smallest victims: in utero drug exposure. , 2002, Forensic science international.

[25]  J. Spagnoli,et al.  Plasma concentrations of the enantiomers of methadone and therapeutic response in methadone maintenance treatment. , 2000, Drug and alcohol dependence.

[26]  Kirsi Vähäkangas,et al.  Ex vivo perfusion of the human placental cotyledon: implications for anesthetic pharmacology , 2000 .

[27]  M. S. Ching,et al.  Fetal hepatic drug elimination. , 1999, Pharmacology & therapeutics.

[28]  A. Negrusz,et al.  Determination of drugs of abuse in meconium. , 1998, Journal of chromatography. B, Biomedical sciences and applications.

[29]  P. Friedmann,et al.  Relationships Between Maternal Methadone Dosage, Maternal-Neonatal Methadone Levels, and Neonatal Withdrawal , 1993, Obstetrics and gynecology.

[30]  N. Buchanan,et al.  Methadone levels and neonatal withdrawal , 1991, Journal of paediatrics and child health.

[31]  H Nau,et al.  Extent of nicotine and cotinine transfer to the human fetus, placenta and amniotic fluid of smoking mothers. , 1985, Developmental pharmacology and therapeutics.

[32]  C. Pippenger,et al.  Pharmacologic observations on the neonatal withdrawal syndrome. , 1976, The Journal of pediatrics.

[33]  M. Strauss,et al.  Methadone maintenance during pregnancy: pregnancy, birth, and neonate characteristics. , 1974, American journal of obstetrics and gynecology.